NCT03346811View on ClinicalTrials.gov

Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer

PHASE2UnknownINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

November 18, 2017

Primary Completion Date

May 10, 2019

Study Completion Date

March 10, 2020

Conditions

Plasma EGFR Mutation-positive Lung Cancer

Interventions

DRUG

Icotinib

Patients with plasma EGFR mutation-positive are arranged to receive icotinib with a dose of 125 mg three times per day, till progressive disease or unaccepted toxicity

Trial Locations (1)

100021

RECRUITING

National Cancer Center/Cancer Hospital, Beijing